Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Cipla
Daiichi Sankyo
Fish and Richardson
US Army
Johnson and Johnson
AstraZeneca
Federal Trade Commission
Express Scripts

Generated: November 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ESTRACE

« Back to Dashboard

Clinical Trials for Estrace

Trial ID Title Status Sponsor Phase Summary
NCT00114517 ELITE: Early Versus Late Intervention Trial With Estradiol Unknown status National Institute on Aging (NIA) Phase 2/Phase 3 The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
NCT00114517 ELITE: Early Versus Late Intervention Trial With Estradiol Unknown status University of Southern California Phase 2/Phase 3 The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
NCT00115024 EPAT: Estrogen in the Prevention of Atherosclerosis Trial Completed Mead Johnson Nutrition Phase 2/Phase 3 The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
NCT00115024 EPAT: Estrogen in the Prevention of Atherosclerosis Trial Completed National Institute on Aging (NIA) Phase 2/Phase 3 The purpose of this study is to determine the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
NCT00465894 Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms Completed Pfizer N/A The purpose of this study is to determine if long acting tolterodine confers more benefit than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12 weeks post-treatment initiation. The hypothesis is that low dose intra-vaginal estrogen confers greater benefit than tolterodine in the treatment of Overactive Bladder symptoms. Secondary outcomes were to assess if the addition of the other therapy to the treatment regimen conferred benefit at 24 weeks and 52 weeks.
NCT00465894 Detrol LA vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms Completed University of Alabama at Birmingham N/A The purpose of this study is to determine if long acting tolterodine confers more benefit than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12 weeks post-treatment initiation. The hypothesis is that low dose intra-vaginal estrogen confers greater benefit than tolterodine in the treatment of Overactive Bladder symptoms. Secondary outcomes were to assess if the addition of the other therapy to the treatment regimen conferred benefit at 24 weeks and 52 weeks.
NCT00661531 Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy Terminated Georgetown University Phase 2 This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Estrace

Condition Name

Condition Name for Estrace
Intervention Trials
Atrophic Vaginitis 3
Atherosclerosis 2
Postmenopause 2
Drug Effects 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Estrace
Intervention Trials
Atrophy 7
Vaginitis 4
Atrophic Vaginitis 3
Atherosclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Estrace

Trials by Country

Trials by Country for Estrace
Location Trials
United States 22
Chile 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Estrace
Location Trials
California 5
Florida 3
Pennsylvania 3
Colorado 2
Virginia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Estrace

Clinical Trial Phase

Clinical Trial Phase for Estrace
Clinical Trial Phase Trials
Phase 4 2
Phase 3 4
Phase 2/Phase 3 2
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Estrace
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 2
Withdrawn 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Estrace

Sponsor Name

Sponsor Name for Estrace
Sponsor Trials
National Institute on Aging (NIA) 2
Merck Sharp & Dohme Corp. 2
National Institutes of Health (NIH) 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Estrace
Sponsor Trials
Other 17
Industry 11
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Citi
Medtronic
Queensland Health
Moodys
Merck
Cipla
Cantor Fitzgerald
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.